Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications

Overview

Journal Front Oncol

Specialty Oncology

Date 2014 Apr 19

PMID 24744989

Citations 51

Authors

Lindsey M Hoffman

Lia Gore

Affiliations

Soon will be listed here.

Abstract

Leukemia is the most common childhood malignancy and acute lymphoblastic leukemia (ALL) represents the largest sub-type. Despite remarkable improvements over the last 40 years, standard therapy fails in 10-20% of newly diagnosed patients. Survival for children with relapsed ALL is poor, and the development and implementation of novel therapeutic strategies in pediatric ALL are critical to further advancements. Immunotherapeutic approaches have been central to more novel ALL therapies. However, more recent innovation in antibody engineering has improved potency and efficacy, and antibody-drug conjugates (ADCs) are an especially attractive option in severely immunocompromised patients. An even more sophisticated antibody design is that of bi-specific T-cell engaging or BiTE(®) antibodies, which directly recruit effector T cells to augment the anti-neoplastic effect. This review focuses on blinatumomab, a bi-specific anti-CD19/CD3 antibody that has shown efficacy in adult patients with precursor B-ALL and is currently being evaluated in the pediatric setting.

Citing Articles

Activation of T Lymphocytes with Anti-PDL1-BiTE in the Presence of Adipose-Derived Mesenchymal Stem Cells (ASCs).

Moeinzadeh L, Ramezani A, Mehdipour F, Yazdanpanah-Samani M, Razmkhah M Biomed Res Int. 2024; 2023:7692726.

PMID: 39282109 PMC: 11401667. DOI: 10.1155/2023/7692726.

Pediatric Acute Lymphoblastic Leukemia Emerging Therapies-From Pathway to Target.

Ivanov A, Alecsa M, Popescu R, Starcea M, Mocanu A, Rusu C Int J Mol Sci. 2023; 24(5).

PMID: 36902091 PMC: 10003692. DOI: 10.3390/ijms24054661.

The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials.

Mocquot P, Mossazadeh Y, Lapierre L, Pineau F, Despas F J Clin Pharm Ther. 2022; 47(9):1337-1351.

PMID: 35906791 PMC: 9796714. DOI: 10.1111/jcpt.13741.

Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma.

Sangsuwannukul T, Supimon K, Chieochansin T, Choomee K, Sujjitjoon J, Junking M PLoS One. 2022; 17(3):e0265773.

PMID: 35312724 PMC: 8936442. DOI: 10.1371/journal.pone.0265773.

Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies.

Dickopf S, Buldun C, Vasic V, Georges G, Hage C, Mayer K Biol Chem. 2022; 403(5-6):495-508.

PMID: 35073465 PMC: 9125802. DOI: 10.1515/hsz-2021-0401.

References

Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N . T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother. 2005; 55(5):503-14. PMC: 11030059. DOI: 10.1007/s00262-005-0001-1. View

Raponi S, De Propris M, Intoppa S, Milani M, Vitale A, Elia L . Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011; 52(6):1098-107. DOI: 10.3109/10428194.2011.559668. View

Loffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T . Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia. 2003; 17(5):900-9. DOI: 10.1038/sj.leu.2402890. View

Gorin N, Isnard F, Garderet L, Ikhlef S, Corm S, Quesnel B . Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study. Eur J Haematol. 2013; 91(4):315-21. DOI: 10.1111/ejh.12154. View

Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S . Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008; 321(5891):974-7. DOI: 10.1126/science.1158545. View

Dreier T, Baeuerle P, Fichtner I, Grun M, Schlereth B, Lorenczewski G . T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol. 2003; 170(8):4397-402. DOI: 10.4049/jimmunol.170.8.4397. View

Fujimoto M, Poe J, Inaoki M, Tedder T . CD19 regulates B lymphocyte responses to transmembrane signals. Semin Immunol. 1998; 10(4):267-77. DOI: 10.1006/smim.1998.9999. View

Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R . Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005; 115(1):98-104. DOI: 10.1002/ijc.20908. View

Nagorsen D, Kufer P, Baeuerle P, Bargou R . Blinatumomab: a historical perspective. Pharmacol Ther. 2012; 136(3):334-42. DOI: 10.1016/j.pharmthera.2012.07.013. View

10.

Leone P, Shin E, Perosa F, Vacca A, Dammacco F, Racanelli V . MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst. 2013; 105(16):1172-87. DOI: 10.1093/jnci/djt184. View

11.

Raetz E, Cairo M, Borowitz M, Blaney S, Krailo M, Leil T . Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol. 2008; 26(22):3756-62. PMC: 2654811. DOI: 10.1200/JCO.2007.15.3528. View

12.

Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou R, Topp M . Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012; 119(26):6226-33. DOI: 10.1182/blood-2012-01-400515. View

13.

Baeuerle P, Reinhardt C . Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009; 69(12):4941-4. DOI: 10.1158/0008-5472.CAN-09-0547. View

14.

Hunger S, Lu X, Devidas M, Camitta B, Gaynon P, Winick N . Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012; 30(14):1663-9. PMC: 3383113. DOI: 10.1200/JCO.2011.37.8018. View

15.

Nguyen K, Devidas M, Cheng S, La M, Raetz E, Carroll W . Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008; 22(12):2142-50. PMC: 2872117. DOI: 10.1038/leu.2008.251. View

16.

Borowitz M, Devidas M, Hunger S, Bowman W, Carroll A, Carroll W . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008; 111(12):5477-85. PMC: 2424148. DOI: 10.1182/blood-2008-01-132837. View

17.

Kong Y, Yoshida S, Saito Y, Doi T, Nagatoshi Y, Fukata M . CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia. 2008; 22(6):1207-13. DOI: 10.1038/leu.2008.83. View

18.

Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A . Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia. 2010; 25(1):181-4. DOI: 10.1038/leu.2010.239. View

19.

Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F . Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer. 2002; 100(6):690-7. DOI: 10.1002/ijc.10557. View

20.

Mack M, Riethmuller G, Kufer P . A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A. 1995; 92(15):7021-5. PMC: 41463. DOI: 10.1073/pnas.92.15.7021. View